87 related articles for article (PubMed ID: 24430489)
1. CXCL-10, interleukin-12 and interleukin-21 are not immunological predictors of HBeAg seroconversion in HIV-1-HBV coinfection following HBV-active antiretroviral therapy.
Giarda P; Avihingsanon A; Sasadeusz J; Audsley J; Marks P; Matthews G; Ruxrungtham K; Lewin SR; Crane M
Antivir Ther; 2014; 19(4):429-33. PubMed ID: 24430489
[TBL] [Abstract][Full Text] [Related]
2. Elevated pre-treatment IL-18 level is associated with HBeAg seroconversion in HIV-HBV coinfection.
Li Y; Xie J; Wang H; Han Y; Wang N; Thio CL; Li T
Antivir Ther; 2017; 22(6):523-527. PubMed ID: 28195558
[TBL] [Abstract][Full Text] [Related]
3. Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.
Matthews GV; Ali RJ; Avihingsanon A; Amin J; Hammond R; Bowden S; Lewin SR; Sasadeusz J; Littlejohn M; Locarnini SL; Ruxrungtham K; Dore GJ
PLoS One; 2013; 8(4):e61297. PubMed ID: 23593455
[TBL] [Abstract][Full Text] [Related]
4. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
[TBL] [Abstract][Full Text] [Related]
5. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
[TBL] [Abstract][Full Text] [Related]
6. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria.
Idoko J; Meloni S; Muazu M; Nimzing L; Badung B; Hawkins C; Sankalé JL; Ekong E; Murphy R; Kanki P; Thio CL
Clin Infect Dis; 2009 Oct; 49(8):1268-73. PubMed ID: 19772386
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
Zoutendijk R; Zaaijer HL; de Vries-Sluijs TE; Reijnders JG; Mulder JW; Kroon FP; Richter C; van der Eijk AA; Sonneveld MJ; Hansen BE; de Man RA; van der Ende ME; Janssen HL
J Infect Dis; 2012 Sep; 206(6):974-80. PubMed ID: 22782950
[TBL] [Abstract][Full Text] [Related]
8. Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort.
Wang H; Li Y; Zhang C; Han Y; Zhang X; Zhu T; Li T
AIDS; 2012 Sep; 26(14):1755-63. PubMed ID: 22614885
[TBL] [Abstract][Full Text] [Related]
9. Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.
Strassl R; Reiberger T; Honsig C; Payer BA; Mandorfer M; Grabmeier-Pfistershammer K; Rieger A; Kundi M; Grundtner P; Peck-Radosavljevic M; Popow-Kraupp T
J Viral Hepat; 2014 Jul; 21(7):508-16. PubMed ID: 24112778
[TBL] [Abstract][Full Text] [Related]
10. Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
Matthews GV; Cooper DA; Dore GJ
Antivir Ther; 2007; 12(1):119-22. PubMed ID: 17503756
[TBL] [Abstract][Full Text] [Related]
11. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy.
Crane M; Oliver B; Matthews G; Avihingsanon A; Ubolyam S; Markovska V; Chang JJ; Dore GJ; Price P; Visvanathan K; French M; Ruxrungtham K; Lewin SR
J Infect Dis; 2009 Apr; 199(7):974-81. PubMed ID: 19231993
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana.
Sagoe KW; Agyei AA; Ziga F; Lartey M; Adiku TK; Seshi M; Arens MQ; Mingle JA
J Med Virol; 2012 Jan; 84(1):6-10. PubMed ID: 22095533
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana.
Chadwick D; Ankcorn M; Sarfo F; Phillips R; Fox Z; Garcia A; Appiah L; Bedu-Addo G; Geretti AM
J Antimicrob Chemother; 2012 Dec; 67(12):2939-42. PubMed ID: 22915461
[TBL] [Abstract][Full Text] [Related]
14. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
Sheng WH; Hung CC; Chang SY; Liu CJ; Chen MY; Hsieh SM; Kao JH; Chen PJ; Chang SC
Clin Infect Dis; 2012 Feb; 54(4):548-55. PubMed ID: 22156858
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.
Maylin S; Boyd A; Lavocat F; Gozlan J; Lascoux-Combe C; Miailhes P; Lassel L; Delaugerre C; Girard PM; Zoulim F; Lacombe K
AIDS; 2012 May; 26(8):939-49. PubMed ID: 22333748
[TBL] [Abstract][Full Text] [Related]
16. Impact of HBV and HCV coinfection on CD4 cells among HIV-infected patients: a longitudinal retrospective study.
Silva CMD; Peder LD; Silva ES; Previdelli I; Pereira OCN; Teixeira JJV; Bertolini DA
J Infect Dev Ctries; 2018 Nov; 12(11):1009-1018. PubMed ID: 32012132
[TBL] [Abstract][Full Text] [Related]
17. HBV pgRNA profiles in Chinese HIV/HBV coinfected patients under pre- and posttreatment: a multicentre observational cohort study.
Xu L; Li X; Lu L; Liu X; Song X; Li Y; Han Y; Zhu T; Cao W; Li T
J Viral Hepat; 2022 Aug; 29(8):616-626. PubMed ID: 35582838
[TBL] [Abstract][Full Text] [Related]
18. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.
Ma SW; Huang X; Li YY; Tang LB; Sun XF; Jiang XT; Zhang YX; Sun J; Liu ZH; Abbott WG; Dong YH; Naoumov NV; Hou JL
J Hepatol; 2012 Apr; 56(4):775-81. PubMed ID: 22173154
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ
Hepatology; 2008 Oct; 48(4):1062-9. PubMed ID: 18697216
[TBL] [Abstract][Full Text] [Related]
20. HBV coinfection is associated with reduced CD4 response to antiretroviral treatment in pregnancy.
Floridia M; Masuelli G; Tamburrini E; Spinillo A; Simonazzi G; Guaraldi G; Degli Antoni AM; Martinelli P; Portelli V; Dalzero S; Ravizza M
HIV Clin Trials; 2017 Mar; 18(2):54-59. PubMed ID: 28067163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
